Redwire Corporation, a leader in space infrastructure for the next-generation space economy, announced that it has launched a new drug development technology and a cancer-detection experiment to the International Space Station (ISS) as the company scales its in-space pharmaceutical drug development program based on the success of its PIL-BOX platform.
To complement the existing PIL-BOX platform, Redwire is launching a high-volume Industrial Crystallizer that is capable of processing samples that are up to 200x the volume of what could previously be processed in the original PIL-BOX technology. The goal is to translate the insights gained from the PIL-BOX investigations into large-scale production for commercial applications. This Industrial Crystallizer technology could provide a roadmap to commercializing the fabrication of materials on the ISS for real-world applications on the ground.
